Consensus Cardinal Health, Inc. Deutsche Boerse AG

Stocks

CLH

US14149Y1082

Pharmaceuticals

Market Closed - Deutsche Boerse AG 02:00:08 2026-10-01 EDT			5-day change	1st Jan Change
195.60 ^EUR	-0.56%		+0.98%	+11.48%

10-01	Cardinal Health renews contract with CVS Health
10-01	Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health	CI

0ca8cbf24cbcc54e99100439.VxwaEX2ldWI3VSF8q8SRmdHMPUZxWCMOGg8LI8wRarU.AmlTezDHB1EPOlARkoLcrLCUCBkHExt4aDloa6FmEMUUXUleIu4tPVkTGQ~8cce9e4e39bea6a9f0357d4b557c8374

Analysts' recommendations: Cardinal Health, Inc.

10-01	Evercore ISI Adjusts PT on Cardinal Health to $270 From $265, Maintains Outperform Rating	MT
08-19	Cardinal Health's Integration of Higher-Margin Services Will Drive Outperformance, RBC Says	MT
08-19	RBC Initiates Cardinal Health at Outperform With $276 Price Target	MT
08-13	Evercore ISI Adjusts Cardinal Health PT to $270 From $265, Maintains Outperform Rating	MT
08-13	TD Cowen Adjusts Cardinal Health Price Target to $280 From $275, Maintains Buy Rating	MT
08-13	JPMorgan Adjusts Cardinal Health Price Target to $260 From $215, Maintains Neutral Rating	MT
08-13	Deutsche Bank Adjusts Cardinal Health Price Target to $261 From $223, Maintains Hold Rating	MT
08-12	Barclays Adjusts Cardinal Health Price Target to $275 From $258, Maintains Overweight Rating	MT
08-12	Evercore ISI Adjusts PT on Cardinal Health to $265 From $270, Maintains Outperform Rating	MT
08-12	UBS Adjusts Price Target on Cardinal Health to $280 From $274, Keeps Buy Rating	MT
08-12	Jefferies Adjusts Price Target on Cardinal Health to $280 From $270, Maintains Buy Rating	MT
08-12	Wells Fargo Adjusts Cardinal Health Price Target to $277 From $245, Maintains Overweight Rating	MT
08-12	Citigroup Adjusts Cardinal Health Price Target to $280 From $265, Maintains Buy Rating	MT
08-12	Leerink Partners Adjusts Cardinal Health PT to $292 From $275, Maintains Outperform Rating	MT
08-12	Evercore ISI Adjusts Cardinal Health PT to $270 From $265, Maintains Outperform Rating	MT
08-12	Mizuho Securities Adjusts Cardinal Health PT to $250 From $240, Maintains Outperform Rating	MT
08-12	Baird Adjusts Cardinal Health Price Target to $274 From $251, Maintains Outperform Rating	MT
08-12	Morgan Stanley Adjusts PT on Cardinal Health to $265 From $255, Keeps Overweight Rating	MT
07-23	Mizuho Adjusts Price Target on Cardinal Health to $240 From $235, Maintains Outperform Rating	MT
07-23	Citigroup Adjusts Price Target on Cardinal Health to $265 From $245, Maintains Buy Rating	MT
07-22	Baird Adjusts Price Target on Cardinal Health to $251 From $248, Maintains Outperform Rating	MT
07-20	UBS Adjusts Price Target on Cardinal Health to $274 From $260, Maintains Buy Rating	MT
07-09	TD Cowen Adjusts Price Target on Cardinal Health to $275 From $255	MT
07-07	Evercore ISI Adjusts Price Target on Cardinal Health to $265 From $240	MT
07-02	BofA Securities Adjusts Cardinal Health Price Target to $260 From $240	MT

More recommendations

Pharmaceuticals Wholesale

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+14.84%
	JOHNSON & JOHNSON					+5.49%
	ABBVIE INC.					+6.6%
	MERCK & CO., INC.					+7.19%
	ROCHE HOLDING AG					+7.52%
	NOVARTIS AG					+5.92%
	ASTRAZENECA PLC					+29.21%
	AMGEN INC.					-7.25%
	GILEAD SCIENCES, INC.					+6.44%
	Average					+8.44%
	Weighted average by Cap.					+9.43%